Blocking a protein called interleukin-11 (IL-11) made old mice live longer and stay healthier. In a Nature study published on 17 July 2024, mice that received an antibody against IL-11 from 75 weeks of age lived 22.5% longer (median) if male and 25% longer if female. According to the same paper, mice born without the gene for IL-11 also lived 24.9% longer on average.
An antibody is a protein that sticks to one precise target, here IL-11, and stops it from working. The treated mice were also leaner, stronger, less frail, and had far fewer tumours at the end of life. The result comes from mice only: no one has yet tested whether blocking IL-11 slows aging in people.
What IL-11 is and why it rises with age
IL-11 is a cytokine, a small messenger protein that cells release to signal to each other. It belongs to the same family as IL-6, a well-known driver of inflammation. The study found that IL-11 levels go up in many cell types and organs as mice get older.
Inside cells, the paper shows that IL-11 turns on two growth and stress switches called ERK and mTORC1, and turns down AMPK, an energy sensor linked to healthy metabolism. These three pathways are among the best-studied levers of aging. mTOR is also the switch blocked by rapamycin, a transplant drug that Gromeus covered in an article on rapamycin and aging in animals.
The work was led by Stuart Cook at the MRC Laboratory of Medical Sciences, Imperial College London, and Duke-NUS Medical School in Singapore. The MRC Laboratory of Medical Sciences said in its release that his team showed in 2018 that IL-11 promotes scarring (fibrosis) and inflammation, against the earlier view that it calmed inflammation.
How the IL-11 study was run
Widjaja and colleagues used two approaches. First, they compared mice whose IL-11 gene (Il11) was deleted from birth with normal littermates. Second, closer to a real treatment, they gave a lab antibody called X203, which neutralizes IL-11, to normal C57BL/6J mice that were already old.
In the healthspan experiment, the paper reports that mice aged 75 weeks were randomized to X203 or a control antibody (IgG) at 40 mg/kg, injected into the belly every 3 weeks for 25 weeks. The authors then examined them at 100 weeks of age. In males, the paper reports 12 mice in the X203 group and 13 in the control group at that point.
In the lifespan experiment, the same paper describes monthly injections of X203 or control antibody at 40 mg/kg, starting at 75 weeks and continuing until each mouse died. The authors say 75 weeks in a mouse corresponds roughly to 55 years in a human.
How much longer mice lived without IL-11
With the antibody, the paper reports a median lifespan of 155.6 weeks in treated mice versus 120.9 weeks in controls, both sexes pooled. The same paper gives 146.4 versus 117.1 weeks in females (25%), and 159.6 versus 130.3 weeks in males (22.5%). The median is the age by which half of the group had died.
Mice lacking the IL-11 gene reached a median of 151 weeks versus 120.9 weeks for normal mice, according to the study. The MRC release rounds the male antibody result to 22.4%, while the paper itself gives 22.5%.
A healthier old age: less frailty and fewer tumours
Lifespan is only part of the result. After 25 weeks of treatment, the paper reports better metabolism and muscle function, lower aging markers, and lower frailty scores in both sexes. Frailty scores count signs of decline such as tremor, fur loss, and walking problems.
Cancer is a common cause of death in old lab mice, and the study counted visible tumours at autopsy. The authors found tumours in 3 of 19 treated mice versus 22 of 36 controls (P = 0.0013). The same paper reports tumours in 3 of 25 mice without the IL-11 gene, versus 49 of 84 normal mice. Age is also the strongest overall cancer risk factor in people, as Gromeus explained in an article on why aging drives cancer risk.
What blocking IL-11 could mean for people
Anti-IL-11 antibodies already exist as experimental drugs. The paper states they are in early-stage clinical trials for fibrotic lung disease, where the lungs become scarred. According to the MRC release, early trial data suggest these drugs are safe, and treated mice showed very few side effects.
Several limits remain. The study used one lab mouse strain and started treatment at a single age, 75 weeks, and the authors write that it is still unknown whether starting later or treating for a short time would work. According to the BBC interview relayed by NDTV, the rare people born unable to make IL-11 can have problems with skull bones, joints, and teeth, so long-term blocking in adults would need careful safety testing. The paper discloses that several authors hold patents on IL-11 antibodies and that Cook co-founded the company Enleofen Bio.
Blocking IL-11 is one of several routes scientists are testing against aging in animals. Gromeus has also covered a brain protein called menin that slowed aging in mice. Check these figures against the sources below before drawing conclusions for your own health.
Sources and related information
Nature – Inhibition of IL-11 signalling extends mammalian healthspan and lifespan – 2024
Widjaja and colleagues, Nature 632, 157-165, published online 17 July 2024 (DOI 10.1038/s41586-024-07701-9). This primary paper is the source of every lifespan, dose, frailty, and tumour figure in this article, and its free full text on PMC gives the methods and disclosures.
MRC Laboratory of Medical Sciences – Inhibiting IL-11 in mice extends healthy lifespan and reduces hallmarks of diseases associated with ageing – 2024
The institutional press release confirms the research team, the 2018 finding on IL-11 and fibrosis, the early safety data in human trials, and the low rate of side effects seen in the mice.
NDTV – Context – Scientists develop breakthrough anti-ageing drug that extends lifespan by 25% – 2024
This news report was the starting point for this article and relays a BBC interview with Stuart Cook. It also mentions the rare people born without IL-11. The figures in this article come from the Nature paper.



